Page 307 - J7107_anmco25_Progr_def_V18

SESSIONI e-POSTER

VENERDÌ 16 MAGGIO

17.30-18.30 - SALA della PIAZZA

P260 - THE RELATIONSHIP BETWEEN CARDIAC STRUCTURE, FUNCTION, AND CLINICAL
OUTCOMES, AND THE IMPACT OF VUTRISIRAN FROM THE HELIOS-B TRIAL
S. Marazia,-K. Jering, M. Fontana, H. Skali, B. Bulwer, O. Lairez, S. Longhi, O. Azevedo,
S. Bender, P. Jay, J. Vest, S. Solomon
Ospedale Vito Fazzi, Lecce; Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts, USA; National
Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, UK; Toulouse University
Hospital, Toulouse, France; Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero–
Universitaria di Bologna, Bologna, Italy; Cardiology Department, Hospital da Senhora da Oliveira, Guimarães, Portugal;
6Alnylam Pharmaceuticals, Cambridge, MA, USA
P261 - IMPACT OF BASELINE HEART FAILURE SEVERITY ON EFFICACY OF VUTRISIRAN
IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY IN THE
HELIOS-B TRIAL: A SUBGROUP ANALYSIS
F. Musca,-M.S. Maurer, R. Witteles, F.H. Sheikh, D.R. Duque, P.Y. Jay, E. Aldinc, S.A. Eraly,
J.D. Gillmore
Asst Ospedale Metropolitano Niguarda, Milano Columbia University Irving Medical Center, New York, NY, USA; Stanford
University School of Medicine, Stanford, CA, USA; MedStar Heart and Vascular Institute, Georgetown University School of
Medicine, Washington DC, USA; Alnylam Pharmaceuticals, Cambridge, MA, USA; National Amyloidosis Centre, UCL, Division
of Medicine, Royal Free Hospital, London, UK
Venerdì 16 MAGGIO 2025

307